Monitoring the Prevalence of Antimicrobial Resistance in Companion Animals: Results from Clinical Isolates in an Italian University Veterinary Hospital
Table 3
Nonsusceptibility percentages for every single tested antimicrobial of the 940 analyzed isolates, from November 2020 to September 2022.
No. of isolates tested (% of total isolates)
Total % of nonsusceptible isolates (total number of nonsusceptible isolates)
Gram + (%)
Gram− (%)
Amikacin
795 (84.57)
11.32 (90)
6.63% (14/211)
13.01% (76/584)
Gentamicin
863 (91.81)
23.06 (199)
33.33% (93/279)
18.15% (106/584)
Ampicillin
789 (83.84)
52.85 (417)
50.56% (180/356)
54.73% (237/433)
Amoxicillin–clavulanate
848 (90.21)
22.99 (195)
20.51% (73/356)
24.80% (122/492)
Piperacillin–tazobactam
940 (100)
15.85 (149)
14.89% (53/356)
16.44% (96/584)
Cefazolin/cephalotin
781 (83.08)
30.73 (240)
21.38% (62/290)
36.25% (178/491)
Ceftiofur
827 (87.98)
25.51 (211)
27.24% (79/290)
24.58% (132/537)
Tetracycline
889 (94.57)
46.68 (415)
62.08% (221/356)
36.40% (194/533)
Erythromycin
290 (30.85)
58.96 (171)
Clindamycin
290 (30.85)
59.65 (173)
Enrofloxacin
940 (100)
48.19 (453)
62.08% (221/356)
39.73% (232/584)
Trimethoprim–sulfamethoxazole
895 (95.21)
27.04 (242)
26.40% (94/356)
27.46% (148/539)
Note: in the first column, the number of isolates tested (excluding intrinsic resistances) and its percentage in relation with the total number of isolates is reported. In the second column, the percentage and the number of nonsusceptible isolates for every tested drug is described. In the third and fourth column, the nonsusceptibility percentages and number (number of nonsusceptible isolates/number of total isolates tested) of isolates identified as Gram positive and Gram negative is reported.
